Johnson and Johnson's new anti-rheumatic biologic, The ® (Golimu mono-anti-injection) is available in China

recently, Johnson and JohnsonCompany(subsidiary Xi'an Yangsen Pharmaceutical co., Ltd.) announced that the company's monthly subcutaneous injection of new anti-rheumatic biological agent Simponi ® (SIMPONI ®), or Golimu mono-resistant injection, has been listed in ChinaThe ® is primarily used to treat adult patients with active synodi spinal itise, and can also be combined with methotrexate (MTX) to treatof anti-rheumatismdrugs, including MTX (adult patients with moderate to severe active rheumatoid arthritis)According to a survey of 1,350 domestic patients with syllades and rheumatoid arthritis who were not met, published in March this year, 70-80% of patients expressed dissatisfaction with the length of treatment;The ® can specifically bind and moderate the excessive risk-promoting cytokines of inflammatory cytokines that can cause inflammation and bone, cartilage and tissue damage to the body , tumor necrosis factors (TNF-a), thereby improving symptoms and signs in patients, inhibiting the progression of structural damage such as bone and joints, and restoring (or at least significantly improving) physical function, quality of life, and social and working skillspatients who have been given medical permission and received proper subcutaneous injection techniques may inject themselves and use them in accordance with the methodprovided in the instructions, the ® has entered more than 120 cities such as Beijing, Shanghai and GuangzhouAt the same time, the patient support project has started a phase of operation, for patients with strong spinal itiser and rheumatoid arthritis to provide pharmacy navigation, near-purchase medicine, delivery of medicine, remoteconsultation(, scienceinformation(and a series of related services